Heat Biologics Inc. Daily Stock Analysis

Daily Stock Analysis, HTBX, Heat Biologics Inc, priceseries

Heat Biologics Inc. Daily Stock Analysis
Stock Information
Open
2.37
Close
2.32
High
2.42
Low
2.29
Previous Close
2.39
Daily Price Gain
-0.07
YTD High
3.59
YTD High Date
Jan 3, 2022
YTD Low
2.29
YTD Low Date
Mar 7, 2022
YTD Price Change
-1.22
YTD Gain
-34.46%
52 Week High
10.85
52 Week High Date
Jun 10, 2021
52 Week Low
2.29
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-5.38
52 Week Gain
-69.87%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 12. 2017
39.90
Sep 29. 2017
44.08
13 Trading Days
10.47%
Link
LONG
Jan 4. 2019
7.49
Jan 24. 2019
9.28
13 Trading Days
23.95%
Link
LONG
Dec 27. 2019
3.25
Jan 2. 2020
3.45
3 Trading Days
5.91%
Link
LONG
Feb 28. 2020
2.31
Mar 10. 2020
4.66
7 Trading Days
101.53%
Link
LONG
Apr 20. 2020
4.18
Apr 21. 2020
4.42
1 Trading Days
5.62%
Link
LONG
May 22. 2020
5.85
Jun 2. 2020
6.33
6 Trading Days
8.19%
Link
LONG
Jun 26. 2020
6.12
Jun 29. 2020
6.70
1 Trading Days
9.43%
Link
LONG
Jul 9. 2020
6.55
Jul 27. 2020
16.87
12 Trading Days
157.57%
Link
LONG
Jan 15. 2021
6.34
Jan 28. 2021
6.95
8 Trading Days
9.64%
Link
Company Information
Stock Symbol
HTBX
Exchange
NasdaqCM
Company URL
http://www.heatbio.com
Company Phone
919-240-7133
CEO
Jeff A. Wolf
Headquarters
North Carolina
Business Address
801 CAPITOLA DRIVE, DURHAM, NC 27713
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001476963
About

Heat Biologics, Inc. operates as a clinical-stage biopharmaceutical company, with interest in the development of novel allergenic drugs. The company focuses on the commercialization of ImPact Therapy, a platform technology that offers a novel approach to treat cancer and other infectious diseases, including HIV, HCV and malaria by using live, genetically-modified, and irradiated human cells to activate the immune system against specific defined targets. Heat Biologics was founded on June 10, 2008 by Jeffrey Alan Wolf and is headquartered in Durham, NC.

Description

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include viagenpumatucel-L (HS-110) that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and vesigenurtacel-L (HS-410), which is in Phase 1b clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading